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TonEBP/NFAT5 haploinsufficiency 
attenuates hippocampal 
inflammation in high-fat diet/
streptozotocin-induced diabetic 
mice
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Dong Hoon Lee1, Hyun Joon Kim1,2, Sang Soo Kang1, Gyeong Jae Cho1, Wan Sung Choi  1,2,  
Soo Youn Choi4, H. Moo Kwon4 & Gu Seob Roh1,2
Recent studies have shown that overexpression of tonicity-responsive enhancer binding protein 
(TonEBP) is associated with many inflammatory diseases, including diabetes mellitus, which causes 
neuroinflammation in the hippocampus as well as hepatic steatosis. However, the exact mechanism in 
diabetic neuroinflammation is unknown. We report that haploinsufficiency of TonEBP inhibits hepatic 
and hippocampal high-mobility group box-1 (HMGB1) expression in diabetic mice. Here, mice were fed 
a high-fat diet (HFD) for 16 weeks and received an intraperitoneal injection of 100 mg/kg streptozotocin 
(STZ) and followed by continued HFD feeding for an additional 4 weeks to induce hyperglycemia and 
hepatic steatosis. Compared with wild-type diabetic mice, diabetic TonEBP+/− mice showed decreased 
body weight, fat mass, hepatic steatosis, and macrophage infiltration. We also found that adipogenesis 
and HMGB1 expression in the liver and hippocampus were lower in diabetic TonEBP+/− mice compared 
with the wild type. Furthermore, iba-1 immunoreactivity in the hippocampus was decreased in 
diabetic TonEBP+/− mice compared with that in the wild type. Our findings suggest that TonEBP 
haploinsufficiency suppresses diabetes-associated hepatic steatosis and neuroinflammation.
Diabetes mellitus (DM) is a common chronic inflammatory disease that causes many complications, such as myo-
cardial infarction, retinopathy, and nephropathy1, 2, and is considered an important risk factor for mild cognitive 
impairment and Alzheimer’s disease3. Diabetes-related obesity leads to the recruitment of large numbers of mac-
rophages and T cells to excess adipose tissue, producing proinflammatory cytokines, as well as advanced glycation 
end-products, and resulting in vascular damage4, 5. This low-grade chronic inflammation is an important risk fac-
tor for systemic insulin resistance and neuroinflammation6, 7. There is evidence that high-fat diet (HFD)-induced 
chronic peripheral inflammation aggravates neuroinflammation and leads to memory impairment8. Thus, the 
inflammatory state may play an important role in the progression of diabetes-induced cognitive changes.
Memory impairment in aged rats with diabetes is exacerbated by inhibiting the signaling of the transcription 
factor nuclear factor-kappa B (NF-κB) in the hippocampus9. However, downregulation of another member of 
the Rel family of transcription factors, the tonicity-responsive enhancer binding protein (TonEBP, also known as 
nuclear factor of activated T cells 5)10, prevents neuronal death in animal models of streptozotocin (STZ)-induced 
diabetic retinopathy11, 12. TonEBP is abundantly expressed in the liver, heart, brain, and kidney, as well as in acti-
vated T cells13–15, and is reduced under hypoosmotic conditions16. TonEBP mediates the release of inflammatory 
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cytokines in macrophages and the induction of cyclooxygenase 2 in kidneys in response to activation of Toll-like 
receptor (TLR) 4 under hypertonic conditions17. We previously showed that in the brain, TonEBP has an inflam-
matory role in the pathology of seizures18. However, the role of TonEBP in modulating diabetic-mediated pathol-
ogy has not been studied. Therefore, we examined the diabetic phenotypes and neuroinflammation in mice with 
TonEBP haploinsufficiency and HFD/STZ-induced diabetes. We identified TonEBP as a critical regulator in 
both hepatic steatosis and neuroinflammation in diabetes and showed that reducing TonEBP expression protects 
against diabetes-induced complications.
Results
Body weight and fat mass gains are attenuated in TonEBP+/− mice with DM. The effects of HFD/
STZ treatment on body weight and fat mass were assessed in mice with TonEBP haploinsufficiency (TonEBP+/−) 
and in wild-type (WT) mice. After 8 weeks on HFD, the body weights of mice with either genotype were signif-
icantly increased compared with those in mice fed a normal diet (P < 0.05), and the body weights of mice fed 
an HFD were slightly reduced after an STZ injection at 16 weeks (Fig. 1a). Although the total food intakes were 
similar (Supplementary Fig. 1a,b), we found that TonEBP+/− mice with DM had lower body weights than WT 
mice with DM (Fig. 1b). In accordance with changes in body weights, the weights of fat mass, and of perirenal and 
mesentery fats, from TonEBP+/− mice with DM were significantly reduced compared with those from WT mice 
with DM (P < 0.05) (Fig. 1c,d).
TonEBP haploinsufficiency attenuates insulin resistance in mice with DM. To determine if 
TonEBP haploinsufficiency alters the diabetic phenotypes in HFD/STZ-treated mice, we measured the fasting 
blood glucose and serum insulin levels and responses to the glucose tolerance test (GTT) and the insulin toler-
ance test (ITT). Animals fed an HFD for 16 weeks showed increased fasting blood glucose levels compared with 
those fed a normal diet. However, there was an increase in blood glucose levels at 20 weeks in WT and TonEBP+/− 
mice with normal diets (Supplementary Fig. 2a). This result indicated that some stressful tests (two independent 
Figure 1. Changes of body weight and metabolic characteristics in HFD/STZ-treated TonEBP+/− mice.  
(a) Body weights of mice for 20 weeks. Body weight (b), fat mass (c), body fats (d), GTT (e), areas under the 
curve (AUC) of GTT (f), ITT (g), and AUC of ITT (h) of WT and TonEBP+/− mice with or without HFD/
STZ treatment were compared. (i) Serum insulin was measured by an ELISA kit. HOMR-IR was calculated 
from fasting serum glucose and insulin. Data (n = 10 mice per group) are shown as the mean ± SEM. (j) 
Representative images showing immunofluorescence of insulin (red) in pancreatic sections. Scale bar = 50 μm. 
(k) Percentage areas of insulin-positive cells. Data are shown as the mean ± SEM. *P < 0.05 vs. control (CTL) 
normal diet-fed mice; †P < 0.05 vs. DM WT mice.
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GTT and ITT at 19 weeks) may have caused temporary increases of blood glucose. In contrast to blood glucose 
levels, we found that there was a significant difference in serum glucose levels between the control (CTL) and 
DM mice (Supplementary Fig. 2b). GTT and ITT analyses showed that insulin resistance was induced by HFD/
STZ treatment (Fig. 1e–h). However, there were no significant changes in serum insulin levels between CTL and 
DM mice (Fig. 1i). To confirm the effects of TonEBP haploinsufficiency on insulin resistance and β-cell function, 
we determined the homeostatic model assessment-insulin resistance (HOMA-IR). HOMA-IR was increased in 
diabetic WT mice compared with those in WT mice with normal diets (Fig. 1i). However, there was slightly 
reduction of HOMA-IR in diabetic TonEBP+/− mice than in diabetic WT mice. We next examined the effect 
of HFD/STZ treatment on pancreatic insulin activity in WT and TonEBP+/− mice by immunostaining with an 
antibody against insulin (Fig. 1j). Compared with normal diet-fed controls, mice with DM exhibited decreased 
percentages of insulin-positive areas (Fig. 1k). Interestingly, the percentage of insulin-positive areas was lower in 
WT mice with DM than in TonEBP+/− mice with DM. To differentiate type 1 DM from type 2 DM, immunohis-
tochemical localization of C-peptide in pancreatic sections were evaluated (Supplementary Fig. 2c). The diabetic 
WT and TonEBP+/− mice exhibited less immunoreactivity of C-peptide compared with normal diet-fed mice 
(Supplementary Fig. 2d). These findings indicated that HFD/STZ caused β-cell dysfunction and loss of β-cells 
resulting in decreased insulin secretion.
TonEBP haploinsufficiency reduces hepatic steatosis and adipogenesis in mice with DM. We 
next performed histological examinations of liver sections and western blot analyses. Hematoxylin and eosin 
(H&E) and Nile red staining showed that hepatic steatosis in WT and TonEBP+/− mice was increased by HFD/
STZ (Fig. 2a). However, the areas (from Nile red-stained sections) containing hepatic lipid droplets were reduced 
in TonEBP+/− mice with DM compared with those in diabetic WT mice (Fig. 2b). Accordingly, we found that 
hepatic triglyceride (TG) concentrations, which were higher in diabetic mice, were lower in mice with TonEBP 
haploinsufficiency (Fig. 2c). Hepatic enzymes were also higher in HFD/STZ-treated mice than in those fed a 
normal diet and were significantly decreased in TonEBP+/− mice with DM compared with the levels in WT mice 
with DM (Supplementary Fig. 3a).
The synthesis of hepatic TG is transcriptionally regulated by the liver X receptor β (LXRβ), sterol regulatory 
element-binding protein 1 (SREBP-1), and peroxisome proliferator-activated receptor α (PPARα)19. We found 
that HFD/STZ treatment increased the hepatic expression of these factors in WT and TonEBP+/− mice, while 
Figure 2. Effects of TonEBP haploinsufficiency on hepatic steatosis in HFD/STZ-treated mice. (a) 
Representative micrographs of H&E and Nile red staining; scale bar = 50 μm. (b) Percentages of Nile red-
positive areas. (c) Concentrations of hepatic TG (n = 7–8 mice per group). Western blotting and quantification 
of nuclear LXRβ (d), SREBP-1 (e), and PPARα (f) in the livers. The mean values were obtained from three 
separate experiments (n = 6 mice per group). Cropped blots are displayed here and full-length blots are 
included in the Supplementary Information. Data are presented as the mean ± SEM. *P < 0.05 vs. control (CTL) 
normal diet-fed mice; †P < 0.05 vs. DM WT mice.
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the increases in LXRβ and PPARα were significantly attenuated by TonEBP haploinsufficiency (Fig. 2d–f). In 
addition, we found that serum total cholesterol levels were higher in mice with DM than in normal diet-fed mice 
(Supplementary Fig. 3b).
HFD/STZ-induced TonEBP is reduced in the livers of TonEBP+/− mice. A previous study showed 
that TonEBP is also expressed in the liver20. We examined the expression levels and localization of TonEBP in 
the liver after HFD/STZ treatment by immunohistochemical staining and western blot analysis. We found that 
TonEBP is weakly expressed in the nuclei of hepatocytes in TonEBP+/− mice compared with that in WT mice and 
highly expressed in the nuclei after HFD/STZ treatment (Fig. 3a). This was confirmed quantitatively by western 
blotting using nuclear fractions of livers from WT and TonEBP+/− mice (Fig. 3b). The expression level of TonEBP 
from nuclear fractions was significantly increased only in HFD/STZ-treated WT mice.
TonEBP is involved in controlling inflammation in response to TLR activation21, 22, and TLR4 is known to 
mediate high-mobility group box-1 (HMGB1) in association with nonalcoholic fatty liver disease23. Thus, we 
examined whether nuclear HMGB1 expression is associated with HFD/STZ-induced hepatic steatosis. Western 
blot analysis showed that nuclear protein levels of HMGB1 were decreased in TonEBP+/− mice with DM com-
pared with that in WT mice with DM (Fig. 3c). The levels of hepatic interleukin-6 (IL-6) and tumor necrosis 
factor- α (TNF-α) expression were also significantly higher in diabetic WT mice compared to normal diet-fed 
WT mice (Fig. 3d,e). Consistent with the HMGB1 findings, two proinflammatory cytokines were significantly 
decreased in diabetic TonEBP+/− mice compared with that in diabetic WT mice. These findings indicated that 
TonEBP haploinsufficiency attenuated HFD/STZ-induced hepatic inflammation. In addition, we found that 
nuclear NF-κB p65 expression was higher in diabetic than in normal diet-fed WT mice; however, there was no 
change with respect to TonEBP haploinsufficiency (Supplementary Fig. 4a).
Macrophage infiltration is reduced in adipose tissues of TonEBP+/− mice. The activation of TLR in 
macrophages requires the induction of TonEBP17. To evaluate the effects of TonEBP haploinsufficiency on mac-
rophage infiltration in HFD/STZ-treated mice, we performed immunohistochemistry for CD68 in adipose tissue 
sections. We found that the size of adipocytes and CD68 immunoreactivity were higher in HFD/STZ-treated 
than in normal diet-fed WT mice; however, CD68 immunoreactivity of macrophages, induced by HFD/STZ, 
was reduced in TonEBP+/− mice (Supplementary Fig. 5a–c). In accordance with hepatic IL-6 expression, we also 
found that the level of IL-6 expression in adipose tissues was decreased in diabetic TonEBP+/− mice compared 
Figure 3. Hepatic TonEBP, HMGB1, IL-6, and TNF-α expression in HFD/STZ-treated TonEBP+/− mice. (a) 
Representative micrographs of TonEBP-immunostained liver sections; scale bar = 50 μm. Western blots and 
protein quantification of hepatic TonEBP (b), HMGB1 (c), IL-6 (d), and TNF-α (e). The mean values were 
obtained from at least three independent experiment (n = 6 mice per group). Cropped blots are displayed here 
and full-length blots are included in the Supplementary Information. Data are presented as the mean ± SEM. 
*P < 0.05 vs. control (CTL) normal diet-fed mice; †P < 0.05 vs. DM WT mice.
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with that in diabetic WT mice (Supplementary Fig. 5d). However, the HFD/STZ-induced TNF-α expression in 
WT mice was slightly reduced in diabetic TonEBP+/− mice (Supplementary Fig. 5e).
HFD/STZ increases TonEBP expression in hippocampal neurons. We next examined the effect of 
DM on the hippocampal expression of TonEBP. To analyze TonEBP expression quantitatively, we performed 
western blotting using hippocampal total lysates and nuclear fractions from WT and TonEBP+/− mice (Fig. 4a,b). 
TonEBP from total lysates was slightly decreased in TonEBP+/− mice (P = 0.37); however, the nuclear expres-
sion level was dramatically decreased in TonEBP+/− mice compared with that in WT mice with normal diets 
(P = 0.007) (Fig. 4b). In particular, we found that TonEBP expression levels from total lysates were increased by 
HFD/STZ in WT mice compared with that in WT mice with normal diet (Fig. 4a). TonEBP expression levels 
from both total lysates and nuclear fractions were dramatically decreased in diabetic TonEBP+/− mice compared 
with that in diabetic WT mice. Accordingly, immunohistochemical staining showed that nuclear TonEBP in hip-
pocampal neurons was increased in WT mice with DM, whereas the expression was relatively weak in TonEBP+/− 
DM mice (Fig. 4c,d). Double immunofluorescence staining showed that NeuN-positive neurons from WT and 
TonEBP+/− mice showed strong TonEBP nuclear staining (Supplementary Fig. 6).
HFD/STZ-induced HMGB1 is abolished in the hippocampi of TonEBP+/− mice. Using western blot 
and immunohistochemical analyses, we next confirmed that DM-induced HMGB1 expression is also reduced in 
the hippocampi TonEBP+/− mice (Fig. 5). Whereas nuclear protein levels of HMGB1 were increased in WT mice 
with DM compared with those in their normal diet-fed counterparts, this increase was abolished in TonEBP+/− 
mice (Fig. 5a). Accordingly, immunoreactivity staining showed that HFD/STZ-induced HMGB1 expression was 
lower in TonEBP+/− hippocampal neurons than in WT mice (Fig. 5b,c). We next investigated HFD/STZ-induced 
proinflammatory cytokines in the hippocampus of WT and TonEBP+/− mice (Fig. 5d). Although there was no 
change in hippocampal IL-6 protein expression between CTL and DM mice, HFD/STZ-treated WT mice exhib-
ited increased hippocampal TNF-α expression compared with normal diet-fed WT mice. However, hippocampal 
TNF-α expression by haploinsufficiency of TonEBP was not significantly reduced in diabetic TonEBP+/− mice. 
Figure 4. Hippocampal TonEBP expression in HFD/STZ-treated TonEBP+/− mice. Western blots and protein 
quantification of total (a) and nuclear (b) TonEBP in the hippocampus. The mean values were obtained 
from three separate experiments (n = 6 mice per group). Cropped blots are displayed here and full-length 
blots are included in the Supplementary Information. Data are presented as the means ± SEM. *P < 0.05 
vs. control (CTL) normal diet-fed mice; †P < 0.05 vs. DM WT mice. (c) Representative micrographs of 
TonEBP immunoreactivity in the hippocampus. TonEBP labeling resembles fine sand grains. The boxed 
areas of a’, b’, c’, and d’ are magnified on the right. Scale bar = 25 μm (inset, 5 μm). (d) The intensity of TonEBP 
immunoreactivity in the hippocampus was measured and presented as the fold change. Data are presented as 
the mean ± SEM. *P < 0.05 vs. control (CTL) normal diet-fed mice; †P < 0.05 vs. DM WT mice.
www.nature.com/scientificreports/
6SCIENTIfIC RepoRts | 7: 7837  | DOI:10.1038/s41598-017-08319-w
In addition, we detected HMGB1 expression in the nuclei of GFAP-positive astrocytes in the hippocampus 
(Supplementary Fig. 7). However, we did not observe a change in GFAP expression with HFD/STZ treatment. In 
accordance with hepatic findings, there was also no significant effect of TonEBP haploinsufficiency on NF-κB p65 
expression with DM (Supplementary Fig. 4b).
HFD/STZ-induced microglial activation is reduced in the hippocampi of TonEBP+/− mice. A 
recent study reported that TonEBP expression in microglia is upregulated in neuroinflammatory dis-
eases24. Similarly, we also observed that TonEBP was detected in iba1-positive microglia in the hippocampus 
(Supplementary Fig. 8). The iba1 immunoreactivity was intense in CA1 and CA3 regions of HFD/STZ-treated 
WT mice but was comparatively dramatically lower in TonEBP+/− mice with DM (Fig. 6a,b). We confirmed sem-
iquantitatively that iba1 expression, which is upregulated upon microglial activation, was increased after HFD/
STZ treatment (Fig. 6c,d).
Discussion
Studies suggest that TonEBP upregulation is associated with many inflammatory diseases, including rheumatoid 
arthritis, atherosclerosis, seizures, lipopolysaccharide-injected brain injury, and diabetes18, 24–26. In this study, 
we demonstrate the role of TonEBP in DM-induced hepatic steatosis and neuroinflammation. We found ele-
vated nuclear expression of TonEBP in diabetic livers and colocalization with HMGB1 in hippocampal neurons. 
We also found that TonEBP+/− mice had reduced levels of hepatic lipogenic factors, HMGB1, IL-6, and TNF-α 
expression, as well as reduced macrophage infiltration and proinflammatory cytokines in adipose tissues of HFD/
STZ-induced diabetes. We showed a significant reduction in iba1 expression in the hippocampi of diabetic mice 
Figure 5. Effects of TonEBP haploinsufficiency on HMGB1, IL-6, and TNF-α expression in the hippocampus 
of HFD/STZ-treated mice. (a) Western blots and protein quantification of nuclear HMGB1 in the hippocampus. 
(b) Representative micrographs of HMGB1 immunoreactivity in the hippocampus. The boxed areas of 
a’, b’, c’, and d’ are magnified on the right. Scale bar = 25 μm (inset, 5 μm). (c) The intensity of HMGB1 
immunoreactivity in the hippocampus was measured and presented as the fold change. (d) Western blots and 
protein quantification of hippocampal IL-6 and TNF-α. The mean values were obtained from three separate 
experiments (n = 6 mice per group). Cropped blots are displayed here and full-length blots are included in the 
Supplementary Information. Data are presented as the mean ± SEM. *P < 0.05 vs. control (CTL) normal diet-
fed mice; †P < 0.05 vs. DM WT mice.
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with TonEBP haploinsufficiency. These findings indicate that TonEBP plays a critical role in the pathology of 
diabetes and that its inhibition significantly reduces HMGB1-mediated inflammation.
Obesity-induced chronic inflammation causes insulin resistance and leads to diabetes through a complex 
series of pathophysiological events characterized by hyperlipidemia, hyperglycemia, hepatic steatosis, systemic 
inflammation, and cognitive dysfunction. We used a mouse model mimicking human T2 diabetes, and charac-
terized by hyperglycemia and abnormal insulin secretion caused by impaired β-cell function and insulin resist-
ance27–30. In our studies, we also showed that chronic HFD-induced hyperinsulinemia was reduced by a single 
STZ injection and this led to a reduction of insulin levels.
In this model, mice were fed an HFD for 20 weeks to induce chronic low-grade inflammation and were then 
injected with STZ for high-glucose-induced hyperosmolarity. We showed that HFD/STZ-treated WT mice have 
higher fat mass, body weight, and serum glucose and cholesterol levels than control mice. Interestingly, there 
were significant reductions of fat mass and body weight in diabetic TonEBP+/− mice compared with those of WT 
mice, although there was no difference in food intake between the groups. These findings suggest that TonEBP is 
an important regulator in adipogenesis.
Diabetes and insulin resistance are associated with nonalcoholic fatty liver disease31, and the livers of obese 
mice overexpress hepatic SREBP-1 and LXR through increased transcriptional regulation of TG synthesis19, 32. In 
addition, PPARα is mainly present in the liver and its activation results in de novo hepatic lipogenesis33. In this 
study, we found that HFD/STZ-induced hepatic steatosis was significantly reduced by TonEBP haploinsufficiency 
and was associated with lower levels of these factors. Our findings are consistent with the fact that hepatic SREBP-
1, LXR, and PPARα expressions are increased in obese db/db mice and reversed by caloric restriction34. However, 
the suppression of DM-induced increases by TonEBP haploinsufficiency contradicts the effect of TonEBP on 
the adipogenesis in 3T3-L1 cells26. This may be due to the difference between in vitro and in vivo functions with 
or without low-grade inflammation (induced by a chronic HFD) and hyperglycemia (induced by STZ). Thus, 
these data indicate that the induction of lipogenic genes in response to insulin and glucose is under the control 
of TonEBP. In this study, we found that increased TonEBP expression in HFD/STZ-induced hepatic steatosis is 
suppressed by TonEBP haploinsufficiency.
A recent report showed that the progression of nonalcoholic steatohepatitis was reduced by inhibiting 
HMGB1–NF-κB translocation35. We found that haploinsufficiency of TonEBP suppressed the HFD/STZ-induced 
upregulation of HMGB1 in hepatic nuclei and attenuated hepatic steatosis. Furthermore, TonEBP haploinsuffi-
ciency abolished the increase in HMGB1 in the hippocampus induced by HFD/STZ treatment. These findings 
Figure 6. Effects of TonEBP haploinsufficiency on iba1 expression in the hippocampus of HFD/STZ-treated 
mice. Representative micrographs of iba1 immunoreactivity in the hippocampal CA3 (a) and CA1 (b) regions. 
The intensity of iba1 immunoreactivity in the hippocampal CA3 (c) and CA1 (d) regions was measured and 
presented as the fold change. Data are presented as the mean ± SEM. *P < 0.05 vs. control (CTL) normal diet-
fed mice; †P < 0.05 vs. DM WT mice. Scale bar = 50 μm.
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are consistent with the significant increase in HMGB1 observed in the spinal dorsal horns of db/db mice36, 
where the blockade of HMGB1 reduced diabetic pain by decreasing the expression of inflammatory mediators. 
Treatment with anti-HMGB1 neutralizing antibodies also reversed neuroinflammation and brain damage in dia-
betic rats with cerebral ischemia37. These data suggest that genetic haploinsufficiency of TonEBP is protective 
against hepatic steatosis and neuroinflammation induced by HMGB1 and TNF-α upregulation. In addition, we 
found that HFD/STZ-induced infiltration of macrophages in adipose tissue was reduced by TonEBP haploinsuf-
ficiency. Indeed, TonEBP haploinsufficiency was shown to significantly reduce atherosclerotic lesion formation 
and macrophage migration in an in vivo model of atherosclerosis25. Consistent with the reduction of IL-6 mRNA 
in macrophages lacking TonEBP17, TonEBP haploinsufficiency reduced the expression of IL-6 proteins in livers 
and adipose tissues of mice with DM.
Recent reports have demonstrated that the expression of TonEBP in neurons increases with acute and pro-
longed systemic hypertonicity38, 39. In this view, we hypothesized that TonEBP regulates osmoprotective neuroin-
flammation in the diabetic brain. Our findings support this hypothesis, showing that the reduction of TonEBP 
in mice with haploinsufficiency reduces HFD/STZ-induced HMGB1 expression. We also observed remarkable 
microglial activation in the hippocampi of HFD/STZ-treated mice, which was attenuated in TonEBP+/− mice. 
Our findings are consistent with a recent report showing that TonEBP is induced in microglia in a rat with tran-
sient middle cerebral artery occlusion and in cultured cells treated with lipopolysaccharide24. Interestingly, inhib-
iting TonEBP significantly protected against microglial activation.
Our study consistently supports the notion that TonEBP haploinsufficiency suppresses neuroinflammation 
in the diabetic brain and reduces steatosis in the liver, suggesting that HFD/STZ-induced TonEBP may be a 
detrimental factor eliciting chronic inflammation. TonEBP functions as a transcriptional activator by binding 
to osmotic response elements of osmoprotective genes13 and interacting with the NF-κB p65 subunit40. In this 
view, we believe that TonEBP haploinsufficiency decreased HMGB1–NF-κB-mediated transcriptional activity 
and attenuated the severity of neuroinflammation. The results from this study suggest that TonEBP haploinsuf-
ficiency may have an anti-inflammatory effect in HFD/STZ-induced diabetes by reducing HMGB1-mediated 
inflammation.
Materials and Methods
Animals. Female and male TonEBP heterozygote (+/−) mice (6 weeks old) were received from Dr. Kwon 
(Ulsan National Institute of Science and Technology). The TonEBP+/− mice were crossed to obtain TonEBP+/− 
mice and their WT (TonEBP+/+) littermates. Animal experiments were performed in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals. The University Animal Care 
Committee for Animal Research of GNU approved the study protocol (GNU-150116-M0002). Mice were housed 
with an alternating 12-h light/dark cycle with food and water available. The diabetic mice were given an HFD 
(60% kcal fat; Research Diets, New Brunswick, NJ, USA) for 16 weeks. After that, mice received a single dose 
(100 mg/kg) of STZ (Sigma-Aldrich, St Louis, MO, USA) dissolved in 0.05 M sodium citrate buffer (pH 4.5) via 
intraperitoneal injection and followed by continued HFD feeding for an additional 4 weeks. WT mice were given 
a normal diet and injected with the sodium citrate buffer vehicle. Mice (n = 10 mice per group) were weighed 
and fasting blood glucose was measured monthly using an Accu-Chek glucometer (Roche Diagnostics GmbH, 
Mannheim, Germany). In addition, food intake (Supplementary Fig. 1) was measured two times each month 
before the animals were sacrificed.
GTT and ITT. GTT and ITT were performed as previously described38. Briefly, d-glucose (2 g/kg; 
Sigma-Aldrich) or insulin (0.75 U/kg; Humulin-R, Eli Lilly, Indianapolis, IN, USA) was injected, and blood glu-
cose was measured before and after the injection using an Accu-Chek glucometer (Roche Diagnostics GmbH).
Measurement of metabolic parameters. After overnight fasting, mice (n = 10 mice per group) were 
deeply anesthetized with zoletil (5 mg/kg; Virbac Laboratories, Carros, France). The resultant serum samples 
were analyzed for serum glucose and aspartate aminotransferase (AST), alanine aminotransferase (ALT), and 
total cholesterol levels using enzymatic colorimetric assays from Green Cross Reference Laboratory (Yongin-si, 
South Korea). Mouse insulin kits (Shibayagi Co., Gunma, Japan) were used to measure insulin levels in serum 
(n = 10 mice per group). TG concentrations from frozen livers (n = 7–8 mice per group) were determined using 
a colorimetric assay kit from Cayman Chemical Company (Ann Arbor, MI, USA). The HOMA-IR was calculated 
from the fasting serum glucose (mg/dL) × fasting plasma insulin (mU/mL) divided by 405.
Tissue analyses and histological staining. Mice (n = 4 mice per group) were perfused with 4% formal-
dehyde solution in 0.1 M phosphate-buffered saline (PBS) through the left ventricle after anesthesia by zoletil 
(5 mg/kg). After postfixation for 6 h, the brains and livers were sequentially immersed in 0.1 M PBS containing 
15% sucrose and then in 30% sucrose at 4 °C until they were completely submerged. Frozen brains were cut into 
coronal sections (40 μm). To determine the intracellular lipid droplets in hepatic steatosis, frozen liver sections 
(10 μm) were stained with Nile red (Sigma, St. Louis, MO, USA) for 10 min. The livers were processed for paraffin 
embedding, and were then sectioned (5 μm) and stained with H&E. Images of the sections were captured using a 
BX51 light microscope (Olympus, Tokyo, Japan).
Western blot analysis. After anesthesia by zoletil (5 mg/kg), hippocampi, liver, epididymal fat pads, and 
pancreas from mice (n = 6 mice per group) were quickly removed and frozen. Whole cellular extracts and nuclear 
fractions were prepared as previously described34. The nuclear fraction was separated by using a Nuclear and 
Cytoplasmic Extraction Kit (Pierce, Rockford, IL, USA) according to the manufacturer’s protocol. Western blot 
analyses were performed using standard methods. Frozen tissues were homogenized in lysis buffer for protein 
extraction. Proteins were immunoblotted with primary antibodies (Supplementary Table 1). The membranes 
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were visualized using an enhanced chemiluminescence substrate (Pierce). The band densitometry was performed 
using a Multi-Gauge V 3.0 image analysis program (Fujifilm, Tokyo, Japan). To normalize the protein levels, p84, 
β-actin, or α-tubulin was used as an internal control.
Immunofluorescence. Free-floating brain and deparaffinized pancreatic sections were incubated with pri-
mary antibodies at 4 °C for overnight (Supplementary Table 1). After washing three times with 0.1 M PBS, sec-
tions were incubated with Alexa Fluor 488-, 594-, and 790-conjugated donkey secondary antibodies (Invitrogen, 
Carlsbad, USA). Nuclei were stained with DAPI (1:10,000; Invitrogen). Fluorescence images of the sections were 
captured using a BX51-DSU microscope (Olympus).
Immunohistochemistry. Free-floating brain, deparaffinized liver, adipose tissue, and pancreatic sections 
were incubated with primary antibodies that were diluted in blocking solution overnight at 4 °C (Supplementary 
Table 1). After three washes with 0.1 M PBS, sections were incubated for 1 h at room temperature with biotiny-
lated secondary antibody. After washing, sections were incubated in an avidin-biotin-peroxidase complex solu-
tion (Vector Laboratories, CA, USA) and developed with diaminobenzidine (Vector Labs) containing 0.025% 
H2O2. Sections were then dehydrated through graded alcohol solutions, cleared in xylene, and mounted under 
a coverslip with Permount (Sigma-Aldrich, St. Louis, MO, USA). Image of the stained sections were captured 
using a BX51 light microscope (Olympus). Immunohistochemical intensity data for insulin, C-peptide, TonEBP, 
HMGB1, and iba-1 were obtained from selected images using i-Solution (IMT i-Solution Inc., Vancouver, BC, 
Canada). Three fields (200 × 200 µm2) were randomly selected on each section from two continuous sections 
(n = 4 mice per group). Intensity measurements are represented as the percentage of the mean number of pixels 
versus the corresponding value at which the pixel of the respective intensity was present.
Statistical analysis. Group differences were determined by one-way analyses of variance (ANOVA) fol-
lowed by Bonferroni post-hoc analyses using PRISM (GraphPad Software Inc., San Diego, CA, USA). Two-way 
ANOVA with repeated measures analyses of variances was used for weight gain, fasting blood glucose, ITT, and 
GTT. Values are expressed as the means ± standard errors of the mean (SEM). A P value < 0.05 was considered 
as statistically significant.
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